Indaptus Therapeutics Stock Performance
| INDP Stock | USD 10.46 0.36 3.33% |
On a scale of 0 to 100, Indaptus Therapeutics holds a performance score of 1. The company retains a Market Volatility (i.e., Beta) of 1.1, which attests to a somewhat significant risk relative to the market. Indaptus Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Indaptus Therapeutics is expected to follow. Please check Indaptus Therapeutics' jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to make a quick decision on whether Indaptus Therapeutics' current trending patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Indaptus Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating fundamental indicators, Indaptus Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.45) | Five Day Return (12.32) | Year To Date Return (58.67) | Ten Year Return (99.93) | All Time Return (99.93) |
Last Split Factor 1:28 | Dividend Date 2020-10-30 | Last Split Date 2025-06-27 |
1 | Acquisition by Gilbert Mark John of 12500 shares of Indaptus Therapeutics at 0.33 subject to Rule 16b-3 | 06/10/2025 |
2 | Indaptus Therapeutics, Inc. Announces Sale of 2.3 Million in Private Placement of Convertible Notes and Warrants | 06/13/2025 |
3 | Why Did Indaptus Therapeutics, Inc. Plunge 11.6 - AInvest | 06/24/2025 |
4 | Indaptus Therapeutics Announces Reverse Stock Split | 06/25/2025 |
5 | Indaptus Therapeutics Sees Trading Pause Due to Volatility INDP Stock News | 06/27/2025 |
6 | Indaptus Therapeutics, Inc. Announces Additional Sale of 3.4 Million in Private Placement of Convertible Notes and Warrants | 07/01/2025 |
7 | Indaptus Therapeutics Inc. Stock Analysis and Forecast - Consistent triple-digit returns - jammulinksnews.com | 07/22/2025 |
| Begin Period Cash Flow | 13.4 M |
Indaptus Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,344 in Indaptus Therapeutics on April 26, 2025 and sell it today you would lose (298.00) from holding Indaptus Therapeutics or give up 22.17% of portfolio value over 90 days. Indaptus Therapeutics is currently generating 0.2548% in daily expected returns and assumes 13.3396% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Indaptus, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Indaptus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Indaptus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Indaptus Therapeutics, and traders can use it to determine the average amount a Indaptus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0191
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INDP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.34 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.25 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Indaptus Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Indaptus Therapeutics by adding it to a well-diversified portfolio.
Indaptus Therapeutics Fundamentals Growth
Indaptus Stock prices reflect investors' perceptions of the future prospects and financial health of Indaptus Therapeutics, and Indaptus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Indaptus Stock performance.
| Return On Equity | -2.59 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 2.16 M | ||||
| Shares Outstanding | 572.66 K | ||||
| Price To Book | 2.14 X | ||||
| EBITDA | (15.02 M) | ||||
| Net Income | (15.02 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 84.16 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 4.89 X | ||||
| Cash Flow From Operations | (12.32 M) | ||||
| Earnings Per Share | (41.44) X | ||||
| Market Capitalization | 5.99 M | ||||
| Total Asset | 7.34 M | ||||
| Retained Earnings | (60.44 M) | ||||
| Working Capital | 3.22 M | ||||
About Indaptus Therapeutics Performance
Assessing Indaptus Therapeutics' fundamental ratios provides investors with valuable insights into Indaptus Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Indaptus Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 49.93 | 44.38 | |
| Return On Tangible Assets | (2.05) | (2.15) | |
| Return On Capital Employed | (3.90) | (3.70) | |
| Return On Assets | (2.05) | (2.15) | |
| Return On Equity | (3.81) | (3.62) |
Things to note about Indaptus Therapeutics performance evaluation
Checking the ongoing alerts about Indaptus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Indaptus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Indaptus Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (15.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Indaptus Therapeutics currently holds about 33.01 M in cash with (12.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0. | |
| Indaptus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 37.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Indaptus Therapeutics Inc. Stock Analysis and Forecast - Consistent triple-digit returns - jammulinksnews.com |
- Analyzing Indaptus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Indaptus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Indaptus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Indaptus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Indaptus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Indaptus Therapeutics' stock. These opinions can provide insight into Indaptus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.